Progress in TB drug development and what is still needed.

Area of Science:

• Microbiology
• Drug Discovery
• Genomics

Background:

• Tuberculosis (TB) treatment relies on drugs over 30 years old, yet mortality is increasing.
• Emergence of multi-drug resistant Mycobacterium tuberculosis necessitates novel therapeutic strategies.
• Recent advances in understanding M. tuberculosis biology, including its genome sequence, provide new avenues for drug development.

Purpose of the Study:

• To highlight the urgent need for new anti-TB drugs, particularly against resistant strains.
• To emphasize the potential of recent scientific advancements in identifying novel drug targets and candidates.
• To call for increased investment and effort in translating basic research into clinical drug discovery.

Main Methods:

• Leveraging the complete M. tuberculosis H37Rv genome sequence and new genetic tools to identify essential genes and potential drug targets.
• Utilizing high-throughput screening and rational drug design to discover lead compounds.
• Developing models of mycobacterial persistence for rapid analysis of sterilizing compounds.

Main Results:

• Identification of numerous essential genes and potential drug targets in M. tuberculosis.
• Discovery of several lead compounds, including the nitroimidazopyran PA-824, a potential drug candidate.
• Advancement in understanding host-pathogen interactions and mycobacterial genetics.

Conclusions:

• Despite progress, a significant gap remains between basic research and clinical application for TB drug discovery.
• Increased resources for medicinal chemistry and development of rapid screening models are crucial.
• Development of surrogate markers for early treatment outcome prediction is needed to facilitate clinical trials.